BAIYUNSHAN PH (00874) announced that its subsidiary, Guangzhou Wanglaoji Pharmaceutical Co., Ltd. (“Wanglaoji Pharmaceutical”), recently held a kickoff meeting for the Phase III clinical trial of Kengangli Yan oral liquid for the treatment of acute pharyngitis (wind-heat syndrome). This Phase III clinical trial has officially commenced. Kengangli Yan oral liquid received its new drug certificate and production approval in 1997 and is a unique product of Wanglaoji Pharmaceutical. It is included in the first part of the 2025 edition of the Pharmacopoeia of the People's Republic of China, known for its abilities to dispel wind, clear heat, and detoxify, primarily used for cold attributed to wind-heat invasion and internal disturbance of pathogenic heat. In February 2024, Wanglaoji Pharmaceutical obtained the clinical trial approval notice issued by the National Medical Products Administration, authorizing the initiation of confirmatory clinical trials for acute pharyngitis (wind-heat syndrome) which corresponds to the Phase III clinical trial. Wanglaoji Pharmaceutical has recently officially launched the Phase III clinical trial.